Biohit Oyj B - Asset Resilience Ratio
Biohit Oyj B (BIOBV) has an Asset Resilience Ratio of 24.24% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read BIOBV total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2004–2025)
This chart shows how Biohit Oyj B's Asset Resilience Ratio has changed over time. See Biohit Oyj B (BIOBV) shareholders funds for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Biohit Oyj B's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Biohit Oyj B.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €3.50 Million | 17.68% |
| Short-term Investments | €1.30 Million | 6.57% |
| Total Liquid Assets | €4.80 Million | 24.24% |
Asset Resilience Insights
- Good Liquidity Position: Biohit Oyj B maintains a healthy 24.24% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Biohit Oyj B Industry Peers by Asset Resilience Ratio
Compare Biohit Oyj B's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
GN Store Nord
CO:GN |
Medical Devices | -4.56% |
|
Novocure Ltd
NASDAQ:NVCR |
Medical Devices | 50.79% |
|
Sino Medical Sciences Technology In
SHG:688108 |
Medical Devices | 0.66% |
|
HOB Biotech Group Corp Ltd
SHG:688656 |
Medical Devices | 2.62% |
|
Zhejiang Orient Gene Biotech Co Ltd
SHG:688298 |
Medical Devices | 2.82% |
|
Dirui Industrial Co Ltd
SHE:300396 |
Medical Devices | 6.89% |
|
EBR Systems Inc
AU:EBR |
Medical Devices | 54.70% |
|
T&R Biofab Co. Ltd
KQ:246710 |
Medical Devices | 0.12% |
Annual Asset Resilience Ratio for Biohit Oyj B (2004–2025)
The table below shows the annual Asset Resilience Ratio data for Biohit Oyj B.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 24.24% | €4.80 Million ≈ $5.61 Million |
€19.80 Million ≈ $23.15 Million |
-19.04pp |
| 2024-12-31 | 43.28% | €6.71 Million ≈ $7.84 Million |
€15.50 Million ≈ $18.12 Million |
-9.46pp |
| 2023-12-31 | 52.74% | €6.81 Million ≈ $7.97 Million |
€12.92 Million ≈ $15.10 Million |
-3.79pp |
| 2022-12-31 | 56.53% | €6.23 Million ≈ $7.28 Million |
€11.02 Million ≈ $12.88 Million |
-0.84pp |
| 2021-12-31 | 57.37% | €5.51 Million ≈ $6.45 Million |
€9.61 Million ≈ $11.24 Million |
+0.96pp |
| 2020-12-31 | 56.41% | €6.08 Million ≈ $7.11 Million |
€10.78 Million ≈ $12.60 Million |
+10.38pp |
| 2019-12-31 | 46.03% | €8.00 Million ≈ $9.35 Million |
€17.37 Million ≈ $20.31 Million |
+1.29pp |
| 2018-12-31 | 44.74% | €8.00 Million ≈ $9.36 Million |
€17.89 Million ≈ $20.91 Million |
+5.71pp |
| 2017-12-31 | 39.03% | €7.38 Million ≈ $8.62 Million |
€18.89 Million ≈ $22.09 Million |
-15.89pp |
| 2016-12-31 | 54.92% | €7.13 Million ≈ $8.34 Million |
€12.99 Million ≈ $15.19 Million |
-0.65pp |
| 2015-12-31 | 55.58% | €6.52 Million ≈ $7.62 Million |
€11.73 Million ≈ $13.71 Million |
-12.04pp |
| 2014-12-31 | 67.62% | €9.81 Million ≈ $11.47 Million |
€14.51 Million ≈ $16.96 Million |
+13.77pp |
| 2013-12-31 | 53.84% | €15.24 Million ≈ $17.82 Million |
€28.30 Million ≈ $33.09 Million |
-21.73pp |
| 2012-12-31 | 75.57% | €30.23 Million ≈ $35.35 Million |
€40.01 Million ≈ $46.77 Million |
+61.58pp |
| 2011-12-31 | 13.99% | €10.00 Million ≈ $11.69 Million |
€71.47 Million ≈ $83.56 Million |
+12.29pp |
| 2010-12-31 | 1.70% | €500.00K ≈ $584.55K |
€29.38 Million ≈ $34.35 Million |
+0.24pp |
| 2009-12-31 | 1.46% | €400.00K ≈ $467.64K |
€27.40 Million ≈ $32.03 Million |
-0.31pp |
| 2008-12-31 | 1.77% | €480.00K ≈ $561.17K |
€27.11 Million ≈ $31.69 Million |
-1.61pp |
| 2007-12-31 | 3.38% | €923.00K ≈ $1.08 Million |
€27.34 Million ≈ $31.96 Million |
+0.24pp |
| 2006-12-31 | 3.13% | €856.00K ≈ $1.00 Million |
€27.32 Million ≈ $31.94 Million |
-5.48pp |
| 2005-12-31 | 8.62% | €2.40 Million ≈ $2.81 Million |
€27.85 Million ≈ $32.56 Million |
+8.63pp |
| 2004-12-31 | -0.02% | €-4.00K ≈ $-4.68K |
€22.76 Million ≈ $26.61 Million |
-- |
About Biohit Oyj B
Biohit Oyj, a biotechnology company, manufactures and sells bind acetaldehyde, diagnostic products, and systems for diagnostic analysis for the use of research institutions, healthcare, and industry worldwide. The company's diagnostic tests product includes the GastroPanel Unified test panel for stomach health check; GastroPanel Four-in-One stomach test; GastroSoft software application to assist … Read more